Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer

Yu,Min; Zhang,Shuang; Huang,Meijuan; Lu,You

doi:10.3892/mco.2014.280

Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer

Authors:
- Min Yu
- Shuang Zhang
- Meijuan Huang
- You Lu
View Affiliations

Affiliations: Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: April 16, 2014 https://doi.org/10.3892/mco.2014.280
Pages: 567-570

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Maintenance therapy with pemetrexed is well tolerated and achieves prolonged progression‑free and overall survival in patients with advanced lung adenocarcinoma. The echinoderm microtubule‑associated protein‑like 4 (EML4)‑anaplastic lymphoma kinase (ALK) is a recently identified fusion oncogene that exists in ~5% of non‑small‑cell lung cancers (NSCLCs). It was demonstrated that ALK‑positive NSCLCs exhibit a high response rate to the ALK inhibitor crizotinib. This is the case report of a patient with NSCLC harboring EML4‑ALK rearrangement, who experienced slowly progressive disease within 4 years of maintenance treatment with pemetrexed and later exhibited a marked response to crizotinib. The sustained clinical benefits suggest further investigations on anticancer agent administration.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24:4539–4544. 2006.PubMed/NCBI
3	Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
4	Paz-Ares L, de Marinis F, Dediu M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 13:247–255. 2012.
5	Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kim SJ, Kim DW, Kim TM, et al: Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. J Clin Oncol. 3:e147–e150. 2012.PubMed/NCBI
7	Camidge DR, Kono SA, Lu X, et al: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 6:774–780. 2011. View Article : Google Scholar : PubMed/NCBI
8	Takeda M, Okamoto I, Sakai K, et al: Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol. 23:2931–2936. 2012. View Article : Google Scholar : PubMed/NCBI
9	Boccalatte FE, Voena C, Riganti C, et al: The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood. 113:2776–2790. 2009. View Article : Google Scholar
10	Kijima T, Takeuchi K, Tetsumoto S, et al: Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. Cancer Sci. 102:1602–1604. 2011. View Article : Google Scholar
11	Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
12	Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 363:1734–1739. 2010. View Article : Google Scholar : PubMed/NCBI